Сулодексид и хронические заболевания почек: результаты экспериментальных и клинических исследований


А.А. Свистунов, В.В. Фомин

ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздрава России, Москва
Обсуждаются результаты экспериментальных и клинических исследований, демонстрирующие нефропротективные свойства сулодексида, в т. ч. его антиальбуминурическое действие.

Литература


1. Nikkila E., Grasbeck R. Heparin in lipoid nephrosis: observations of the effects on edema, proteinuria, serum proteins, lipids and lipoproteins. Acta Med Scand. 1954; 150(1): 39–46.
2. Poplawski A. Effect of heparin on proteinuria and other biochemical parameters in nephrotic syndrome. Pol Tyg Lek. 1974;29(10):289–291.
3. Кутырина И.М., Никишова Т.В., Тареева И.Е. Гипотензивное и диуретическое действие гепарина у больных хроническим гломерулонефритом. Тер. арх. 1985; 6: 78–81.
4. Mandal A.K., Lyden T.W., Saklaen M.G. Heparin lowers blood pressure. Kidney Int. 1995; 47: 1017–1022.
5. Козловская Н.Л. Низкомолекулярные гепарины в практике нефролога. Клин. нефрология. 2011; 1: 15–22.
6. Козловская Н.Л., Шилов Е.М., Шахнова Е.А. и др. Низкомолекулярные гепарины в лечении АФС-нефропатии при первичном и вторичном антифосфолипидном синдроме. Тер. арх. 2004; 9: 35–40.
7. Gambaro G., Baggio B. Glycosaminoglicans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol. Dial. Transplant. 1996; 11: 762–764.
8. Benck U., Haeckel S., Clorius J.H. et al. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensinaldosterone system. Clin J Am Soc Nephrol. 2007; 2(1): 58–67.
9. Harvey S.J., Miner J.H. Revisiting the glomerular charge barrier in the molecular era. Curr Opin Nephrol Hypertens. 2008; 17: 393–398.
10. van der Born J., van del Havuel L., Bakker M. et al. Distribution of GBM heparin sulphate proteoglycan core protein and side chanins in human glomerular disease. Kidney Int. 1993;43: 454–463.
11. Tamsma J., van der Born J., Bruijn J. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparin sulphate in the glomerular basal membrane. Diabetologia. 1994;37:313–320.
12. Raats C., Luca M., Bakker M. et al. Reduction in glomerular heparin sulphate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol. 1999; 10: 1689–1699.
13. Pillarisetti S. Lipoprotein modulation of seubendothelial heparin sulphate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000; 10: 60–65.
14. van der Hoven M.J., Rops A.L., Vladovsky I. et al. Heparanase in glomerular diseases. Kidney Int. 2007;72:543–548.
15. Lewis E.J., Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy, implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31(Suppl. 2): S202–S207.
16. Wijnhoven T.J., van den Hoven M.J., Ding H. et al. Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008;51:372–382.
17. Jensen T. Pathogenesis of diabetic vascular disease, evidence for the role of reduced heparin sulphate proteoglycan. Diabetes. 1997; 46 (Suppl. 2): S98–S100.
18. Wijnhoven T.J., Lensen J.F., Rops A.L. et al. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007;9:364–377.
19. Ruggeri A., Guizzardi S., Franchi M. et al. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats. Arzneimittelforschung. 1985; 35: 1517–1519.
20. Karon J., Połubinska A., Antoniewicz A.A. et al. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif. 2007; 25: 510–514.
21. Ciszewicz M., Polubinska A., Antoniewicz A. t al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009; 153: 118–123.
22. Kristova V., Liskova S., Sotnikova R. et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57:491– 494.
23. Rossini M., Naito T., Yang H. et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant. 2010; 25(6):1803–1810.
24. Yung S., Chau M.K., Zhang Q. et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocininduced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501.
25. Jin H.Y., Lee K.A., Song S.K. et al. Sulodexide prevents peripheral nerve damage in streptozocin induced diabetic rats. Eur J Pharmacol. 2012; 674(2–3): 217–226.
26. Li P., Ma L.L., Xie R.J. et al. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. Acta Pharmacol Sin. 2012; 33(5): 644–651.
27. Solini A., Vergnani L., Ricci F. et al. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997; 20(5): 819–823.
28. Sorrenti G., Grimaldi M., Canova N. et al. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997; 25(2): 81–86.
29. Skrha J., Perusicova J., Pontuch P. et al. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1): 25–31.
30. Шестакова М.В., Чугунова Л.А., Воронцов А.В. и др. Эффективность сулодексида – низкомолекулярного гепарина – в терапии диабетической нефропатии. Тер. арх. 1997;6:34–37.
31. Gambaro G., Kinalska I., Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002; 13(6): 1615–1625.
32. Achour A., Kacem M., Dibej K. et al. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005; 18(5):568–574.
33. Sulikowska B., Olejniczak H., Muszynska M. et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006; 26(6): 621–628.
34. Heerspink H.L., Greene T., Lewis J.B. et al.; Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946–1954.
35. Packham D.K., Wolfe R., Reutens A.T. et al.; Collaborative Study Group. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1): 123–130.
36. Lewis E.J., Lewis J.B., Greene T. et al.; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011; 58(5): 729–736.
37. House A.A., Weir M.A. Sulodexide for diabetic nephropathy: another one bites the dust. Am J Kidney Dis. 2011; 58(5): 692–694.
38. Blouza S., Dakhli S., Abid H. et al.; DAVET (Diabetic Albuminuria Vessel Tunisia Study Investigators). Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010; 23(4): 415–424.
39. Masola V., Onisto M., Zaza G. et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012; 10: 213.


Об авторах / Для корреспонденции


Свистунов А.А. – профессор, проректор по учебной работе, заведующий кафедрой фармакологии фармацевтического факультета ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздрава России, д.м.н.;
Фомин В.В. – профессор, декан лечебного факультета, профессор кафедры терапии и профболезней медико-профилактического факультета ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздрава России, д.м.н.


Похожие статьи


Бионика Медиа